SCHEMBL16018282

SCHEMBL16018282

CCCOP(Cl)N(C(C)C)C(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1391357 0.81
SCHEMBL10087269 0.80
SCHEMBL13805531 0.77 ODC1 (0.31)
SCHEMBL19890099 0.76 HSD17B10 (0.31)
SCHEMBL12767708 0.76 HSD17B10 (0.31)
SCHEMBL416419 0.75
SCHEMBL285592 0.75 TSHR (0.30)
SCHEMBL12731238 0.74 HSD17B10 (0.30)
SCHEMBL19930034 0.74 TSHR (0.32)
Hydrochloric Acid SCHEMBL2951043 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279041-A1 FUNCTIONALIZED N-ACETYLGALACTOSAMINE ANALOGS HONGENE BIOTECH CORPORATION 2023-09-07 US disclosed
US-20230016929-A1 EXTRAHEPATIC DELIVERY BANK OF AMERICA, N.A. 2023-01-19 US disclosed
US-10953105-B2 Immunostimulatory compositions and methods of use thereof MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2021-03-23 US disclosed
US-20190015522-A1 IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2019-01-17 US disclosed
US-20160348110-A1 NUCLEIC ACID CHEMICAL MODIFICATIONS ALNYLAM PHARMACEUTICALS INC (US) 2016-12-01 US disclosed
US-9345780-B2 Site specific delivery of nucleic acids by combining targeting ligands with endosomolytic components TEKMIRA PHARMACEUTICALS CORPORATION (CA) 2016-05-24 US disclosed
US-9090648-B2 Cationic oligonucleotides, automated methods for preparing same and their uses CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2015-07-28 US disclosed
US-20140256785-A1 SITE SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS TEKMIRA PHARMACEUTICALS CORPORATION (CA) 2014-09-11 US disclosed